Coronavirus Notebook: Regeneron, HHS To Develop Antibody
China Domestics Step Up R&D Efforts
Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.
You may also be interested in...
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.
US antiviral specialist Gilead is working to provide its experimental drug remdesivir to treat the China coronavirus, while other potential treatments and alliances continue to emerge, including between Wuhan-based BravoVax and US venture GeoVax.